Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Decreases By 47.3%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totaling 57,108 shares, a decrease of 47.3% from the June 30th total of 108,461 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 69,290 shares, the short-interest ratio is currently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management acquired a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,481 shares of the company’s stock, valued at approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Stock Down 1.4%

Shares of IDNA stock traded down $0.46 during mid-day trading on Friday, reaching $32.33. The stock had a trading volume of 40,633 shares, compared to its average volume of 43,186. iShares Genomics Immunology and Healthcare ETF has a one year low of $20.93 and a one year high of $34.97. The firm has a market cap of $190.75 million, a PE ratio of 14.76 and a beta of 0.92. The firm’s 50 day simple moving average is $31.64 and its 200 day simple moving average is $30.20.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.